Related Experiment Video
Updated: Jun 26, 2026
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
Published on: March 18, 2015
Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells
Helen M Pettersson1, Alexander Pietras, Matilda Munksgaard Persson
1Center for Molecular Pathology, CREATE Health, Department of Laboratory Medicine, Lund University, University Hospital MAS, Entrance 78, SE-205 02 Malmö, Sweden. helen.pettersson@med.lu.se
Abstract:
Small cell lung carcinoma (SCLC) is an extremely aggressive form of cancer and current treatment protocols are insufficient. SCLC have neuroendocrine characteristics and show phenotypical similarities to the childhood tumor neuroblastoma. As multidrug-resistant neuroblastoma cells are highly sensitive to arsenic trioxide (As2O3) in vitro and in vivo, we here studied the cytotoxic effects of As2O3 on SCLC cells. As2O3 induced pronounced cell death in SCLC cells at clinically relevant concentrations, and also at hypoxia. SCLC cells were more sensitive than non-SCLC cells to As2O3. Cell death was mainly due to necrosis, although apoptotic responses were also seen. A significant in vivo effect of As2O3 on SCLC growth was shown in a nude mice-xenograft model, although a fraction of the treated tumor-bearing animals did not respond. The nonresponding SCLC tumors differed in morphology and cell organization compared with treatment-responsive tumors, which in turn, showed decreased vascularization and higher expression of neuroendocrine markers compared with control tumors. Our results suggest a potential clinical application of As2O3 in SCLC therapy. In addition to cell death induction, antiangiogenic induction of differentiation may also be part of the in vivo effect of As2O3 on SCLC growth, as suggested by an increase in neuroendocrine markers in cultured cells.
Insights
Arsenic trioxide (As2O3) demonstrates significant cytotoxic effects against small cell lung carcinoma (SCLC) cells, offering a potential new therapeutic avenue for this aggressive cancer. Studies show As2O3 effectively reduces SCLC tumor growth in vivo.
Area of Science:
- Oncology
- Cancer Research
- Pharmacology
Background:
- Small cell lung carcinoma (SCLC) is a highly aggressive cancer with limited treatment options.
- SCLC shares neuroendocrine characteristics with neuroblastoma, a childhood tumor.
- Multidrug-resistant neuroblastoma cells show sensitivity to arsenic trioxide (As2O3).
Purpose of the Study:
- To investigate the cytotoxic effects of arsenic trioxide (As2O3) on small cell lung carcinoma (SCLC) cells.
- To evaluate the efficacy of As2O3 as a potential therapeutic agent for SCLC.
Main Methods:
- In vitro studies on SCLC cell lines exposed to As2O3 at various concentrations, including hypoxic conditions.
- In vivo studies using a nude mice-xenograft model to assess As2O3's effect on SCLC tumor growth.
- Analysis of tumor morphology, cell organization, vascularization, and neuroendocrine marker expression in response to treatment.
Main Results:
- As2O3 induced significant cell death in SCLC cells at clinically relevant concentrations and under hypoxic conditions.
- SCLC cells exhibited greater sensitivity to As2O3 compared to non-SCLC cells.
- In vivo studies demonstrated a significant reduction in SCLC tumor growth, though some tumors were unresponsive.
- Responsive tumors showed decreased vascularization and increased neuroendocrine markers, suggesting differentiation and antiangiogenic effects.
Conclusions:
- Arsenic trioxide (As2O3) shows promise as a potential therapeutic agent for small cell lung carcinoma (SCLC).
- The anti-cancer effects of As2O3 in SCLC may involve both direct cell death induction and antiangiogenic differentiation.
- Further clinical investigation is warranted to explore As2O3's role in SCLC treatment.
